Credit Suisse resumed coverage on Galecto with a new price target
$GLTO
Biotechnology: Pharmaceutical Preparations
Health Care
Credit Suisse resumed coverage of Galecto with a rating of Outperform and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2021 | $12.00 → $7.00 | Outperform | Credit Suisse |
BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025. "During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML," said Dr. Hans Schambye, CEO of Galecto. "We continued preclinical studies to support our planned IND submission, which remains on track for Q1 2026. To date, preclinical data have shown significant improvement in efficacy compared to current FLT3 and menin inhibitors, with activity acro
Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge MedicinesGB3226 on track for IND submission in Q1 2026Phase 2 investigator-initiated trial (IIT) of GB1211 in combination with pembrolizumab (Keytruda®) in metastatic melanoma and head and neck squamous cell carcinoma continues to enroll patients BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial r
BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One MeetingsDate and Time: Wednesday, February 12 at 8:40-9:10 AM Location: Virtual A live webcast of the presentation will be available via the Upcoming Events section of the Company's investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay wi
Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously
Credit Suisse resumed coverage of Galecto with a rating of Outperform and set a new price target of $12.00
Credit Suisse Group reiterated coverage of Galecto with a rating of Outperform and set a new price target of $12.00 from $29.00 previously
8-K - Galecto, Inc. (0001800315) (Filer)
10-Q - Galecto, Inc. (0001800315) (Filer)
DEFA14A - Galecto, Inc. (0001800315) (Filer)
4 - Galecto, Inc. (0001800315) (Issuer)
4 - Galecto, Inc. (0001800315) (Issuer)
4 - Galecto, Inc. (0001800315) (Issuer)